Speaker Profile
M.D., Ph.D., Head of Global Product Development and Chief Medical Officer, Roche
Biography
Levi Garraway is a global leader in precision oncology, with a career spanning groundbreaking research, biotech innovation, and executive leadership in drug development.
At Roche, he oversees one of the industry’s most advanced pipelines. Under his leadership, Roche has deepened its use of genetic and molecular data to guide clinical understanding. Roche has also pioneered the use of real-world data and AI across the R&D continuum to guide discovery and development of new therapies.
Previously, Levi was on faculty at Dana-Farber Cancer Institute, Harvard Medical School and the Broad Institute, where his lab helped define early cancer mutation landscapes, identify therapeutic vulnerabilities, and characterize mechanisms of resistance to cancer therapies. During that time, Levi co-founded Foundation Medicine (now part of the Roche Group), a leading genomics-based cancer diagnostics company that has transformed precision oncology practice worldwide.
Levi has authored 200+ scientific publications. He serves on the board of trustees for the Dana-Farber Cancer Institute and advisory boards for MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and the American Association for Cancer Research.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
